Co-Diagnostics, Inc. (NASDAQ:CODX) Short Interest Down 65.7% in June

Posted by Geri Gentry on Jun 28th, 2026

Co-Diagnostics, Inc. (NASDAQ:CODX – Get Free Report) saw a significant decline in short interest in June. As of June 15th, there was short interest totaling 119,689 shares, a decline of 65.7% from the May 31st total of 349,389 shares. Currently, 3.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,199,824 shares, the short-interest ratio is currently 0.1 days.

Co-Diagnostics Stock Performance

CODX stock traded up $0.01 on Friday, hitting $3.06. 100,593 shares of the company’s stock were exchanged, compared to its average volume of 999,864. Co-Diagnostics has a 12-month low of $1.26 and a 12-month high of $46.50. The stock has a market cap of $11.29 million, a P/E ratio of -0.19 and a beta of 2.74. The firm has a 50 day moving average price of $3.51 and a two-hundred day moving average price of $3.66.

Co-Diagnostics (NASDAQ:CODX – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($4.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.75) by ($0.31). Co-Diagnostics had a negative net margin of 6,760.63% and a negative return on equity of 164.92%. The firm had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.13 million.

Hedge Funds Weigh In On Co-Diagnostics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC boosted its holdings in Co-Diagnostics by 393.8% in the 3rd quarter. Virtu Financial LLC now owns 126,524 shares of the company’s stock worth $44,000 after buying an additional 100,901 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Co-Diagnostics by 314.1% in the 2nd quarter. Jane Street Group LLC now owns 166,254 shares of the company’s stock worth $47,000 after acquiring an additional 126,105 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Co-Diagnostics by 40.4% during the 4th quarter. Geode Capital Management LLC now owns 449,148 shares of the company’s stock worth $81,000 after acquiring an additional 129,158 shares during the period. 14.99% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CODX has been the topic of a number of recent research reports. Weiss Ratings downgraded shares of Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Wall Street Zen raised Co-Diagnostics to a “sell” rating in a research report on Saturday, May 23rd. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $67.50.

Get Our Latest Report on Co-Diagnostics

About Co-Diagnostics

(Get Free Report)

Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.